abt-737 and Leukemia

abt-737 has been researched along with Leukemia* in 2 studies

Reviews

1 review(s) available for abt-737 and Leukemia

ArticleYear
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
    Journal of medicinal chemistry, 2010, Oct-14, Volume: 53, Issue:19

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics

2010

Other Studies

1 other study(ies) available for abt-737 and Leukemia

ArticleYear
Structure-activity relationship and molecular mechanisms of ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4h-chromene-3-carboxylate (sha 14-1) and its analogues.
    Journal of medicinal chemistry, 2009, Oct-08, Volume: 52, Issue:19

    Rapid development of multiple drug resistance against current therapies is a major barrier in the treatment of cancer. Therefore, anticancer agents that can overcome acquired drug resistance in cancer cells are of great importance. Previously, we have demonstrated that ethyl 2-amino-4-(2-ethoxy-2-oxoethyl)-6-phenyl-4H-chromene-3-carboxylate (5a, sHA 14-1), a stable analogue of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (6, HA 14-1), mitigates drug resistance and synergizes with a variety of cancer therapies in leukemia cells. Structure-activity relationship (SAR) studies of 5a guided the development of ethyl 2-amino-6-(3',5'-dimethoxyphenyl)-4-(2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (5q, CXL017), a compound with low micromolar cytotoxicity against a wide-range of hematologic and solid tumor cells. More excitingly, our studies of 5q in camptothecin (CCRF-CEM/C2) and mitoxantrone (HL-60/MX2) resistant cancer cells highlight its ability to selectively kill drug-resistant cells over parent cancer cells. 5q inhibits tumor cell growth through the induction of apoptosis, with detailed mechanism of its selectivity toward drug-resistant cancer cells under investigation. These results suggest that 5q is a promising candidate for treatment of cancers with multiple drug resistance.

    Topics: Apoptosis; Benzopyrans; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Humans; Leukemia; Mitoxantrone; Structure-Activity Relationship

2009